Sensus Healthcare (SRTS) Competitors

$3.03 +0.09 (+3.06%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.04 +0.01 (+0.33%)

As of 07/24/2026 06:40 PM Eastern

SRTS vs. EMBC, LUCD, KRMD, INFU, and APYX

Should you buy Sensus Healthcare stock or one of its competitors? MarketBeat compares Sensus Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensus Healthcare include Embecta (EMBC), Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), InfuSystem (INFU), and Apyx Medical (APYX). These companies are all part of the "medical equipment" industry.

How does Sensus Healthcare compare to Embecta?

Sensus Healthcare (NASDAQ:SRTS) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Sensus Healthcare presently has a consensus target price of $6.88, suggesting a potential upside of 126.90%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 234.35%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Embecta had 33 more articles in the media than Sensus Healthcare. MarketBeat recorded 34 mentions for Embecta and 1 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat Embecta's score of 0.08 indicating that Sensus Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Sensus Healthcare	Very Positive
Embecta	Neutral

Embecta has a net margin of 10.73% compared to Sensus Healthcare's net margin of -34.50%. Sensus Healthcare's return on equity of -15.79% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
Embecta	10.73%	-23.96%	14.12%

Sensus Healthcare has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Embecta has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Embecta has higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$22.53M	2.21	-$7.72M	-$0.47	N/A
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73

Summary

Embecta beats Sensus Healthcare on 9 of the 16 factors compared between the two stocks.

How does Sensus Healthcare compare to Lucid Diagnostics?

Sensus Healthcare (NASDAQ:SRTS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sensus Healthcare has higher revenue and earnings than Lucid Diagnostics. Sensus Healthcare is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$22.53M	2.21	-$7.72M	-$0.47	N/A
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A

In the previous week, Lucid Diagnostics had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 2 mentions for Lucid Diagnostics and 1 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat Lucid Diagnostics' score of 0.58 indicating that Sensus Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Sensus Healthcare	Very Positive
Lucid Diagnostics	Positive

Sensus Healthcare has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Sensus Healthcare currently has a consensus price target of $6.88, suggesting a potential upside of 126.90%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 361.38%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Sensus Healthcare has a net margin of -34.50% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Summary

Sensus Healthcare beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Sensus Healthcare compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

KORU Medical Systems has a net margin of -5.27% compared to Sensus Healthcare's net margin of -34.50%. KORU Medical Systems' return on equity of -13.61% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

KORU Medical Systems has higher revenue and earnings than Sensus Healthcare. KORU Medical Systems is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$43.26M	4.07	-$2.64M	-$0.05	N/A
Sensus Healthcare	$22.53M	2.21	-$7.72M	-$0.47	N/A

In the previous week, KORU Medical Systems had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 2 mentions for KORU Medical Systems and 1 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat KORU Medical Systems' score of 0.93 indicating that Sensus Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
KORU Medical Systems	Positive
Sensus Healthcare	Very Positive

KORU Medical Systems currently has a consensus target price of $7.25, indicating a potential upside of 89.30%. Sensus Healthcare has a consensus target price of $6.88, indicating a potential upside of 126.90%. Given Sensus Healthcare's higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

KORU Medical Systems has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

KORU Medical Systems beats Sensus Healthcare on 11 of the 16 factors compared between the two stocks.

How does Sensus Healthcare compare to InfuSystem?

Sensus Healthcare (NASDAQ:SRTS) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

In the previous week, InfuSystem had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 2 mentions for InfuSystem and 1 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat InfuSystem's score of 0.00 indicating that Sensus Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Sensus Healthcare	Very Positive
InfuSystem	Neutral

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InfuSystem has a net margin of 1.12% compared to Sensus Healthcare's net margin of -34.50%. InfuSystem's return on equity of 2.78% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
InfuSystem	1.12%	2.78%	1.41%

Sensus Healthcare currently has a consensus price target of $6.88, indicating a potential upside of 126.90%. InfuSystem has a consensus price target of $15.00, indicating a potential upside of 64.47%. Given Sensus Healthcare's higher probable upside, analysts plainly believe Sensus Healthcare is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$22.53M	2.21	-$7.72M	-$0.47	N/A
InfuSystem	$142.40M	1.29	$870K	$0.38	24.00

Sensus Healthcare has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Summary

InfuSystem beats Sensus Healthcare on 12 of the 16 factors compared between the two stocks.

How does Sensus Healthcare compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 15.9% of Apyx Medical shares are held by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Apyx Medical has a net margin of -16.40% compared to Sensus Healthcare's net margin of -34.50%. Sensus Healthcare's return on equity of -15.79% beat Apyx Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-16.40%	-88.47%	-14.94%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

Sensus Healthcare has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$55.90M	2.94	-$11.21M	-$0.22	N/A
Sensus Healthcare	$22.53M	2.21	-$7.72M	-$0.47	N/A

In the previous week, Apyx Medical had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 2 mentions for Apyx Medical and 1 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat Apyx Medical's score of 0.94 indicating that Sensus Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Apyx Medical	Positive
Sensus Healthcare	Very Positive

Apyx Medical has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Apyx Medical currently has a consensus target price of $6.60, indicating a potential upside of 68.37%. Sensus Healthcare has a consensus target price of $6.88, indicating a potential upside of 126.90%. Given Sensus Healthcare's higher possible upside, analysts plainly believe Sensus Healthcare is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Apyx Medical beats Sensus Healthcare on 10 of the 17 factors compared between the two stocks.

Get Sensus Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRTS vs. The Competition

Export

Metric	Sensus Healthcare	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$48.40M	$7.30B	$6.87B	$12.26B
Dividend Yield	N/A	1.33%	2.67%	9.79%
P/E Ratio	-6.45	48.63	27.14	23.64
Price / Sales	2.21	96.88	517.08	89.45
Price / Cash	N/A	25.71	50.54	59.64
Price / Book	1.03	6.73	10.28	6.07
Net Income	-$7.72M	$162.27M	$3.60B	$331.99M
7 Day Performance	0.33%	-5.05%	-1.27%	-0.63%
1 Month Performance	2.71%	-5.86%	-0.37%	-2.00%
1 Year Performance	-45.01%	-2.88%	18.30%	13.62%

Sensus Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRTS Sensus Healthcare	3.2774 of 5 stars	$3.03 +3.1%	$6.88 +126.9%	-46.4%	$48.40M	$22.53M	N/A	40	Positive News
EMBC Embecta	4.3967 of 5 stars	$3.34 -3.1%	$11.00 +229.8%	-71.1%	$199.05M	$1.08B	1.77	1,850	Trending News
LUCD Lucid Diagnostics	3.1908 of 5 stars	$0.97 -0.2%	$4.19 +333.0%	-17.5%	$196.98M	$4.71M	N/A	70
KRMD KORU Medical Systems	3.5602 of 5 stars	$4.01 -1.2%	$7.25 +80.8%	+9.1%	$184.18M	$41.13M	N/A	80
INFU InfuSystem	3.3466 of 5 stars	$9.12 +2.0%	$15.00 +64.6%	+54.3%	$183.96M	$142.40M	151.94	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRTS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensus Healthcare (SRTS) Competitors

SRTS vs. EMBC, LUCD, KRMD, INFU, and APYX

How does Sensus Healthcare compare to Embecta?

Summary

How does Sensus Healthcare compare to Lucid Diagnostics?

Summary

How does Sensus Healthcare compare to KORU Medical Systems?

Summary

How does Sensus Healthcare compare to InfuSystem?

Summary

How does Sensus Healthcare compare to Apyx Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRTS vs. The Competition

Sensus Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensus Healthcare (SRTS) Competitors

SRTS vs. EMBC, LUCD, KRMD, INFU, and APYX

How does Sensus Healthcare compare to Embecta?

Do analysts rate SRTS or EMBC?

Do insiders & institutionals have more ownership in SRTS or EMBC?

Does the media favor SRTS or EMBC?

Is SRTS or EMBC more profitable?

Which has more volatility and risk, SRTS or EMBC?

Which has preferable earnings and valuation, SRTS or EMBC?

Summary

How does Sensus Healthcare compare to Lucid Diagnostics?

Do insiders and institutionals believe in SRTS or LUCD?

Which has preferable valuation and earnings, SRTS or LUCD?

Does the media favor SRTS or LUCD?

Which has more risk & volatility, SRTS or LUCD?

Do analysts prefer SRTS or LUCD?

Is SRTS or LUCD more profitable?

Summary

How does Sensus Healthcare compare to KORU Medical Systems?

Is KRMD or SRTS more profitable?

Which has higher valuation & earnings, KRMD or SRTS?

Does the media prefer KRMD or SRTS?

Do analysts prefer KRMD or SRTS?

Do institutionals & insiders believe in KRMD or SRTS?

Which has more volatility & risk, KRMD or SRTS?

Summary

How does Sensus Healthcare compare to InfuSystem?

Does the media favor SRTS or INFU?

Do institutionals and insiders believe in SRTS or INFU?

Is SRTS or INFU more profitable?

Do analysts prefer SRTS or INFU?

Which has higher valuation & earnings, SRTS or INFU?

Which has more risk and volatility, SRTS or INFU?

Summary

How does Sensus Healthcare compare to Apyx Medical?

Do insiders and institutionals believe in APYX or SRTS?

Is APYX or SRTS more profitable?

Which has better valuation and earnings, APYX or SRTS?

Does the media prefer APYX or SRTS?

Which has more volatility and risk, APYX or SRTS?

Do analysts prefer APYX or SRTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRTS vs. The Competition

Sensus Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools